| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 68.3 | 70.4 |
| Profit before tax | -29.7 | -203.0 |
| Net income | -31.4 | -202.4 |
| EPS (diluted, $ a share) | $-0.19 | $-1.25 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -3.0% |
|---|---|
| Operating margin | -45.8% |
10-Q filed with the SEC, NASDAQ: NVAX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Novavax Inc: key numbers
- Share price
- $8.06Close, Nov 16
- Market cap
- $1.33B
- Shares outstanding
- 165.01MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Novavax Inc
All →Novavax Financial Results
Novavax reported Q3 2026 total revenue of $68 million and raised its full-year 2026 revenue guidance to $400 million at the mid-point. The company also earned a $125 million milestone payment from partner Sanofi following the initiation of a Phase 3 combination vaccine trial in Europe.
“This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.”
John C. Jacobs, President and Chief Executive Officer, Novavax
Novavax Business Update
Novavax earned a $125 million milestone payment from Sanofi following the dosing of the fifth patient in a Phase 3 influenza-COVID-19 combination vaccine trial in the European Union. The trial utilizes Novavax's Nuvaxovid COVID-19 component in combination with Sanofi's high-dose flu vaccine. Novavax expects to receive the payment by the first quarter of 2027 and remains eligible for further clinical and regulatory milestones.
- Counterparty
- Sanofi Pasteur Inc.